Drug profile

The FDA adverse-event record for Insulin Injectable Cartridge

188 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Insulin Injectable Cartridge. See the species affected, top reactions, and outcomes below.

188
adverse-event reports
9.0%
death-coded share
Dog
most-reported species
88
INEFFECTIVE, GLYCEMIC CONTROL - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
188
Total Reports
17
Deaths Reported
9.0%
Death Rate

Active Ingredients

Insulin Injectable Cartridge

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 117
Unknown 35
Cat 35
Human 1

Most Affected Breeds

Unknown 36
Crossbred Canine/dog 26
Domestic Shorthair 24
Beagle 9
Domestic Longhair 7
Chihuahua 7
Maltese 7
Bichon Frise 7
Terrier - Yorkshire 7
Schnauzer - Miniature 7

Most Reported Reactions

INEFFECTIVE, GLYCEMIC CONTROL 88
Hypoglycaemia 33
Lack of efficacy - NOS 27
Containers, Damaged 23
INEFFECTIVE, LOSS OF EFFECT 15
Death by euthanasia 14
Lethargy (see also Central nervous system depression in 'Neurological') 13
Vomiting 10
Decreased appetite 10
Containers, Leaking 10
Diarrhoea 9
Emesis (multiple) 9

Outcome Breakdown

Ongoing
59 (38.6%)
Recovered/Normal
50 (32.7%)
Recovered with Sequela
17 (11.1%)
Euthanized
14 (9.2%)
Outcome Unknown
10 (6.5%)
Died
3 (2.0%)

Insulin Injectable Cartridge Adverse Event Insights

188 reports name Insulin Injectable Cartridge; 17 recorded a death outcome (9.0% of reported events, not a population-level mortality rate). Active ingredient: Insulin Injectable Cartridge. Administration routes: Subcutaneous, Unknown.

By species: Dog (117 reports), Unknown (35 reports), Cat (35 reports). By breed: Unknown (36), Crossbred Canine/dog (26), Domestic Shorthair (24).

Leading clinical signs: INEFFECTIVE, GLYCEMIC CONTROL (88), Hypoglycaemia (33), Lack of efficacy - NOS (27), Containers, Damaged (23). Outcome, 153 coded reports: Ongoing leads at 38.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.